U.S. markets close in 2 hours 34 minutes
  • S&P 500

    4,421.47
    +65.02 (+1.49%)
     
  • Dow 30

    34,590.11
    +292.38 (+0.85%)
     
  • Nasdaq

    13,871.12
    +331.82 (+2.45%)
     
  • Russell 2000

    2,035.05
    +31.02 (+1.55%)
     
  • Crude Oil

    87.23
    +1.63 (+1.90%)
     
  • Gold

    1,829.70
    -22.80 (-1.23%)
     
  • Silver

    23.78
    -0.11 (-0.46%)
     
  • EUR/USD

    1.1301
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    1.7800
    -0.0030 (-0.17%)
     
  • GBP/USD

    1.3511
    +0.0005 (+0.04%)
     
  • USD/JPY

    114.3070
    +0.4410 (+0.39%)
     
  • BTC-USD

    37,742.07
    +413.90 (+1.11%)
     
  • CMC Crypto 200

    865.26
    +9.45 (+1.10%)
     
  • FTSE 100

    7,469.78
    +98.32 (+1.33%)
     
  • Nikkei 225

    27,011.33
    -120.01 (-0.44%)
     

Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • GLPG.AS
  • Galapagos NV (NASDAQ: GLPG) announced results of two post-hoc analyses from the SELECTION and SELECTION LTE studies of filgotinib for active ulcerative colitis (UC).

  • The analyses showed clinical benefits of continued dosing with filgotinib 200mg, an oral once-daily JAK1 preferential inhibitor, in patients who did not respond at week 10.

  • Additionally, treatment with filgotinib 200mg resulted in clinically meaningful improvements in health-related quality of life (HRQoL) measures by week 58.

  • The data will be presented at the UEGW virtual 2021 congress.

  • A post-hoc analysis of the SELECTION study showed that continuous filgotinib 200mg among non-responders resulted in 65.7% biologic-naïve and 62.2% biologic-experienced patients achieving partial Mayo Clinic Score (pMCS) response by Week 12.

  • 17.1% biologic-naïve and 16.7% biologic-experienced patients in pMCS remission.

  • Related: Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease.

  • Price Action: GLPG stock is down 1.66% at $50.32 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.